CLB Stock Analysis: Core Laboratories | NYSE

Reservoir Description, Production Enhancement, Well Diagnostics, Carbon Capture

Total Rating 40

Safety 83

Buy Signal -0.66

Oil & Gas Equipment & Services
Industry Rotation: +18.1

Market Cap: 477M
Avg Turnover: 8.72M

Risk 3d forecast

Volatility51.8%

VaR 5^th Pctl8.78%

VaR vs Median2.91%

Reward TTM

Sharpe Ratio0.24

Rel. Str. IBD4.4

Rel. Str. Peer Group3.8

Character TTM

Beta0.928

Beta Downside1.455

Hurst Exponent0.513

Drawdowns 3y

Max DD62.50%

CAGR/Max DD-0.40

CAGR/Mean DD-0.68

EPS (Earnings per Share)

EPS CAGR: -8.06%
EPS Trend: -71.8%

Last SUE: 1.20
Qual. Beats: 1

Revenue

Rev. CAGR: 0.95%
Rev. Trend: 74.2%

Last SUE: -0.13
Qual. Beats: 0

Warnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +4.5% 8

Feb -1.3% 28

Mar +2.5% 19

Apr -3.7% 20

May -0.2% 5

Jun +1.2% 17

Jul -0.3% 5

Aug -9.1% 43

Sep -0.3% 13

Oct -1.3% 11

Nov +2.2% 11

Dec +1.6% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CLB Core Laboratories

Core Laboratories (NYSE: CLB) is a Houston-based provider of reservoir description and production enhancement services to the oil and gas industry, operating domestically and internationally since its founding in 1936. The company is organized into two segments: Reservoir Description, which offers laboratory-based analytical and field services to characterize reservoir rock and fluids, and Production Enhancement, which provides services and products for well completions, perforations, stimulations, production, and well abandonment. Within the broader Energy sector (GICS sub-industry: Oil & Gas Equipment & Services), CLB supplies specialized technical inputs to upstream exploration and production operators rather than producing hydrocarbons itself.

In addition to its core oil and gas offerings, Core Laboratories extends its reservoir analysis capabilities into adjacent areas such as carbon capture, utilization and storage (CCUS), geothermal energy projects, and mining evaluation, reflecting how oilfield services firms increasingly apply subsurface expertise to energy transition applications. The company markets its products and services through a multi-channel approach combining direct sales representatives, technical seminars, trade shows, print advertising, and third-party distributors.

Headlines to Watch Out For

Global E&P capital spending drives Reservoir Description segment revenue
Crude oil prices and U.S. completions activity boost Production Enhancement demand
Energy transition services in CCUS and geothermal expand revenue mix
Share repurchases and dividends support capital return to shareholders

Piotroski VR-10 (Strict) 5.5

Net Income: 24.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.93 > 1.0
NWC/Revenue: 21.82% < 20% (prev 25.69%; Δ -3.86% < -1%)
CFO/TA 0.05 > 3% & CFO 28.2m > Net Income 24.4m
Net Debt (152.4m) to EBITDA (62.8m): 2.43 < 3
Current Ratio: 2.12 > 1.5 & < 3
Outstanding Shares: last quarter (46.9m) vs 12m ago -1.33% < -2%
Gross Margin: 16.75% > 18% (prev 16.71%; Δ 0.03% > 0.5%)
Asset Turnover: 87.34% > 50% (prev 85.93%; Δ 1.41% > 0%)
Interest Coverage Ratio: 4.36 > 6 (EBIT TTM 48.0m / Interest Expense TTM 11.0m)

Altman Z'' 3.72

A: 0.19 (Total Current Assets 214.4m - Total Current Liabilities 101.0m) / Total Assets 586.8m
B: 0.29 (Retained Earnings 172.7m / Total Assets 586.8m)
C: 0.08 (EBIT TTM 48.0m / Avg Total Assets 594.4m)
D: 0.91 (Book Value of Equity 278.8m / Total Liabilities 308.0m)
Altman-Z'' = 3.72 = AA

Beneish M -3.15

DSRI: 0.85 (Receivables 108.8m/128.0m, Revenue 519.2m/517.4m)
GMI: 1.00 (GM 16.71% / 16.75%)
AQI: 1.01 (AQ_t 0.35 / AQ_t-1 0.35)
SGI: 1.00 (Revenue 519.2m / 517.4m)
TATA: -0.01 (NI 24.4m - CFO 28.2m) / TA 586.8m)
Beneish M = -3.15 (Cap -4..+1) = AA

What is the price of CLB shares?

As of August 06, 2026, the stock is trading at USD 10.95 with a total of 541,089 shares traded. Over the past week, the price has changed by +10.94%, over one month by -1.26%, over three months by -22.99% and over the past year by +2.15%.

Current recommended Stop Loss: 10.10 (which is 7.8% or 1.3 ATR below the current price).

Is CLB a buy, sell or hold?

Core Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CLB.

StrongBuy: 0
Buy: 1
Hold: 3
Sell: 1
StrongSell: 0

What are the forecasts/targets for the CLB price?

Analysts Target Price	15.5	41.6%

Core Laboratories (CLB) - Fundamental Data Overview as of 01 August 2026

Market Cap USD = 477.1m (477.1m USD * 1.0 USD.USD)
P/E Trailing = 16.1719
P/E Forward = 17.1821
P/S = 0.9092
P/B = 1.6921
P/EG = 1.4441
Revenue TTM = 519.2m USD
EBIT TTM = 48.0m USD
EBITDA TTM = 62.8m USD
Long Term Debt = 110.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.5m USD (from shortTermDebt, last fiscal year)
Debt = 175.1m USD (corrected: LT Debt 110.3m + ST Debt 11.5m) + Leases 53.4m
Net Debt = 152.4m USD (calculated: Debt 175.1m - CCE 22.7m)
Enterprise Value = 629.5m USD (477.1m + Debt 175.1m - CCE 22.7m)
Interest Coverage Ratio = 4.36 (Ebit TTM 48.0m / Interest Expense TTM 11.0m)
EV/FCF = 29.20x (Enterprise Value 629.5m / FCF TTM 21.6m)
FCF Yield = 3.42% (FCF TTM 21.6m / Enterprise Value 629.5m)
FCF Margin = 4.15% (FCF TTM 21.6m / Revenue TTM 519.2m)
Net Margin = 4.69% (Net Income TTM 24.4m / Revenue TTM 519.2m)
Gross Margin = 16.75% ((Revenue TTM 519.2m - Cost of Revenue TTM 432.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 16.19%)
Tobins Q-Ratio = 1.07 (Enterprise Value 629.5m / Total Assets 586.8m)
Interest Expense / Debt = 6.28% (Interest Expense 11.0m / Debt 175.1m)
Taxrate = 32.89% (12.1m / 36.8m)
NOPAT = 32.2m (EBIT 48.0m * (1 - 32.89%))
Current Ratio = 2.12 (Total Current Assets 214.4m / Total Current Liabilities 101.0m)
Debt / Equity = 0.63 (Debt 175.1m / totalStockholderEquity, last quarter 278.8m)
Debt / EBITDA = 2.43 (Net Debt 152.4m / EBITDA 62.8m)
Debt / FCF = 7.07 (Net Debt 152.4m / FCF TTM 21.6m)
Total Stockholder Equity = 271.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.10% (Net Income 24.4m / Total Assets 586.8m)
RoE = 8.98% (Net Income TTM 24.4m / Total Stockholder Equity 271.2m)
RoCE = 12.57% (EBIT 48.0m / Capital Employed (Equity 271.2m + L.T.Debt 110.3m))
RoIC = 6.78% (NOPAT 32.2m / Invested Capital 474.4m)
WACC = 7.90% (E(477.1m)/V(652.2m) * Re(9.25%) + D(175.1m)/V(652.2m) * Rd(6.28%) * (1-Tc(0.33)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -80.62 | Cagr: -0.77%
[DCF] Terminal Value 73.10% ; FCFF base≈28.8m ; Y1≈25.3m ; Y5≈20.4m
[DCF] Fair Price = 3.81 (EV 328.0m - Net Debt 152.4m = Equity 175.6m / Shares 46.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -71.75 | EPS CAGR: -8.06% | SUE: 1.20 | # QB: 1
Revenue Correlation: 74.24 | Revenue CAGR: 0.95% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.15 | Chg30d=-13.89% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.43 | Chg30d=-20.37% | Revisions=+0% | GrowthEPS=-42.7% | GrowthRev=-3.0%
EPS next Year (2027-12-31): EPS=0.68 | Chg30d=-21.05% | Revisions=-25% | GrowthEPS=+57.0% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -25% (up=0, down=1)